Search clinical trials for: GORE® BIO-A® Tissue Reinforcement

Total 1180 results

Inge Marie Svane

Completed

T-cell Based Immunotherapy for of Melanoma

Melanoma

Denmark
Inge Marie Svane

Withdrawn

T-cell Based Immunotherapy for Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma

Denmark
Federal Budgetary Research Institution State Research...

Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
University Hospital Tuebingen
AstraZeneca; German Federal Ministry of Education and Research; German Center...

Recruiting

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Renal Failure | PreDiabetes | Type2diabetes

Germany
Allergan

Completed

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Muscle Spasticity

Poland, Canada, Korea, Republic of, Czech Republic, Germany, Hungary, United States, Russian Federation, United Kingdom
St. Jude Children's Research Hospital

Completed

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

Healthy Participants

United States
Assistance Publique Hopitaux De Marseille

Unknown

Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors (PROVIN)

Pediatric Cancer

France
Mutual Pharmaceutical Company, Inc.

Completed

Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets

Healthy | Therapeutic Equivalency
Sanofi

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Meningococcal Immunisation (Healthy Volunteers)

Japan
Bial - Portela C S.A.

Completed

Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation

United States, Puerto Rico
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis. (PEP2)

HIV Infections

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Gilead Sciences
Boehringer Ingelheim

Terminated

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)

United States
Duke University

Terminated

Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines

Cancer
Johannes Gutenberg University Mainz
Roche Pharma AG

Completed

Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen (PADD-ON)

Chronic Hepatitis B

Germany
Vertex Pharmaceuticals Incorporated

Terminated

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Hepatitis C

Canada, United States
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Portugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
Allergan

Completed

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Overactive Bladder

Poland, United Kingdom, Portugal, South Africa, Ukraine, Australia, Netherlands, Canada, Singapore, Russian Federation, Germany, Brazil, Austria, Slovakia, Czechia, United States, Taiwan, Italy, France, Belgium, Spain, New Zealand
University Hospital, Clermont-Ferrand
Centre Jean Perrin

Unknown

Rest/Stress Quantification Of Left Ventricular Dyssynchrony By 3D Gated Blood Pool D-SPECT

Left Ventricular Dyssynchrony

France
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

United Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
Allergan

Completed

Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia

Cervical Dystonia

Poland, Germany, United States, Serbia, South Africa, Taiwan, Canada, Singapore, Russian Federation, Czech Republic, Thailand, Hungary, Philippines, United Kingdom, India, Slovakia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

Healthy

Germany
Washington University School of Medicine

Terminated

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
Allergan

Completed

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

Urinary Incontinence

United States, Belgium, Czechia, Canada, France, Italy, Poland, Turkey
Allergan

Completed

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

Urinary Incontinence

United States, Belgium, Canada, Poland, Italy, France, Czechia, Turkey
Allergan

Completed

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

Lateral Canthal Lines | Crow's Feet Lines

Korea, Republic of
Allergan

Completed

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Overactive Bladder | Urinary Incontinence

Poland, United Kingdom, Belgium, Canada, Russian Federation, United States, Germany, Czechia
Allergan

Completed

Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder (BOREAL)

Urinary Bladder, Overactive | Urinary Bladder, Neurogenic

France
Allergan

Completed

A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine

Migraine Disorders

Korea, Republic of
Allergan

Withdrawn

A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines

Chronic Migraine, Headache
Allergan

Completed

Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

Stroke | Muscle Spasticity

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome (PreCISe)

Multiple Sclerosis
Oslo University Hospital
Sunnaas Rehabilitation Hospital

Completed

Prevention of Bladder Dysfunction in Acute Spinal Cord Injury (BOT-SCI)

Urinary Bladder, Overactive | Spinal Cord Injuries

Norway
Allergan

Completed

Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

Urinary Bladder, Overactive

United States
Allergan

Completed

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

Stroke | Cerebral Palsy | Muscle Spasticity | Pediatrics

United States, Korea, Republic of, Thailand, Hungary, Philippines, Poland, Russian Federation, Canada, Turkey
Allergan

Completed

Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines

Glabellar Rhytides

China
Allergan

Completed

BOTOX® Prophylaxis in Patients With Chronic Migraine

Migraine Disorders

United Kingdom, Sweden, Germany, Spain
Allergan

Withdrawn

Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

Migraine Disorders
Allergan

Completed

A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine

Migraine Disorders

United States, Australia, Korea, Republic of
Allergan

Completed

Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea

Urinary Bladder, Overactive | Urinary Incontinence

Korea, Republic of
Allergan

Completed

An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder (GRACE)

Urinary Bladder, Overactive | Urinary Incontinence

United Kingdom, Germany, Spain, Sweden
Biolab Sanus Farmaceutica

Completed

Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face (XEO-001/07)

Skin Aging

Brazil
Allergan

Completed

A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

Chronic Migraine, Headaches

United States
Allergan

Withdrawn

Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Stroke | Muscle Spasticity
Allergan

Completed

Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function

Stroke | Motor Neuron Disease | Muscle Spasticity

Poland, United States, Czech Republic, Hungary
Allergan

Completed

Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia

Torticollis

Croatia
Allergan

Completed

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Hyperhidrosis

United States, Sweden, United Kingdom, Germany
University of Arkansas
Amgen

Terminated

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Multiple Myeloma

United States

3

Subscribe